Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Phosphodiesterase Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Phosphodiesterase Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Phosphodiesterase inhibitors are a class of medications that block the action of phosphodiesterase enzymes, which regulate the levels of cyclic nucleotides, particularly cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). By inhibiting these enzymes, phosphodiesterase inhibitors can modulate intracellular signaling pathways and have diverse therapeutic effects. Phosphodiesterase inhibitors prevent the breakdown of cAMP and cGMP, thereby increasing their intracellular concentrations. Elevated levels of these cyclic nucleotides lead to various downstream effects, including smooth muscle relaxation, vasodilation, bronchodilation, and anti-inflammatory actions. The specific phosphodiesterase isoform targeted by each inhibitor determines its selectivity and therapeutic effects. Phosphodiesterase inhibitors have multiple clinical applications. For instance, phosphodiesterase-5 (PDE-5) inhibitors like sildenafil and tadalafil are commonly used to treat erectile dysfunction by enhancing vasodilation and blood flow to the penile tissues. PDE-3 inhibitors, such as milrinone and inamrinone, are employed in managing heart failure, increasing contractility and vasodilation, improving cardiac output. In addition, phosphodiesterase inhibitors have been investigated for their potential in treating other conditions, including pulmonary hypertension, asthma, chronic obstructive pulmonary disease (COPD), and Raynaud's disease, among others. Extensive research is being conducted globally to discover new and novel molecules to be used, like roflumilast, that is used for the treatment of many indications like COPD. The development and launch of new products will thus increase the market's revenue in the forecasted years.
Several of these inhibitors are in the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 140 products in various stages of clinical trials – 15 in Phase 4, 13 in Phase 3, 9 in Phase 2, and 2 in Phase 1 of the clinical trials.
Key Developments Of Phosphodiesterase Inhibitor
Approved Phosphodiesterase Inhibitor molecules
Drugs in the Pipeline of Phosphodiesterase Inhibitor
Clinical Activity and Developments of Phosphodiesterase Inhibitor
As of July 2023, various companies have approximately 140 products for 669 diseases. For these diseases, many trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Simdax (levosimendan IV) |
118 |
|
Daliresp (roflumilast) |
97 |
|
Eucrisa (crisaborole) |
40 |
|
Zydena (udenafil) |
40 |
|
Eyevinal (ibudilast) |
27 |
Phosphodiesterase inhibitors have a wide range of clinical indications. Among their primary uses, phosphodiesterase-5 (PDE-5) inhibitors like sildenafil and tadalafil find significant application in the treatment of erectile dysfunction (ED), a condition characterized by the inability to achieve or maintain an erection. These medications enhance the effects of nitric oxide, promoting smooth muscle relaxation and increased blood flow to the penis. Phosphodiesterase inhibitors have shown efficacy in the treatment of pulmonary arterial hypertension (PAH), a progressive condition that affects the blood vessels in the lungs. PDE-5 inhibitors, along with other targeted therapies, help dilate pulmonary arteries, reduce pulmonary vascular resistance, and improve exercise capacity in patients with PAH. Furthermore, phosphodiesterase inhibitors such as theophylline and roflumilast are utilized in the management of chronic obstructive pulmonary disease (COPD). They help relax the smooth muscles of the airways, leading to bronchodilation and improved airflow, thus alleviating symptoms and reducing exacerbations in COPD patients.
Orion's global net sales of Simdax in fiscal year 2022 were 43 million Euros that was 25% lower than global net sales in fiscal year 2021. The drop in the sales is because of the competition from the generics. AstraZeneca’s Daliresp has also seen a decline in its sales since the last year. Daliresp’s 2021 sales fell down by 17% to $189 million in the financial year 2022, while a decline to $26 million by 52% was seen in the sales of the 4th quarter of 2022. The prevalence of Pulmonary Arterial Hypertension (PAH) is around 16 to 20 ppm within the USA and Europe, wherein Idiopathic, Heritable and anorexigen-iinduced cases make up to 52.^% of all PAH cases. However, significant progress has been made to finding novel molecules for the treatment of PAH, discovery of better approaches is awaited.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Simdax (levosimendan IV), Daliresp (roflumilast), Eucrisa (crisaborole) and Zydena (udenafil) are approved Phosphodiesterase Inhibitor drugs.
These are used for the treatment of Erectile dysfunction (ED), Pulmonary Arterial Hypertension (PAH), COPD and many more
AbbVie, AstraZeneca, Takeda Pharmaceuticals, Pfizer and Mezzion Pharma are some of the major market players for Phosphodiesterase Inhibitor.
Rising incidence of diseases improvement in technologies, development of new treatment lines in the market and rising incidence of various types of diseases like Erectile dysfunction (ED), Pulmonary Arterial Hypertension (PAH), COPD and others are the key opportunities for Phosphodiesterase Inhibitor in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.